Neonatal Thyroid Screening

graph TD
    A[Newborn Screening for Congenital Hypothyroidism] --> B{Timing of Screening}
    
    B -->|< 24 hours| C[High risk of False Positives<br>due to physiologic TSH surge]
    B -->|2 to 4 days of life| D[Perform Dried Blood Spot DBS<br>via heelprick]
    
    D --> E{Screening Strategy}
    
    E -->|Primary TSH Strategy| F[Measures TSH only.<br>Detects Primary CH.<br>Misses Central CH.]
    E -->|Primary T4 + Reflex TSH| G[Measures Total T4.<br>If low, reflex TSH performed.<br>Detects Primary & Central CH.]
    
    F --> H{Analyze TSH Levels}
    G --> H
    
    H -->|TSH > 40 mU/L| I[Immediate referral & treatment.<br>Do not delay for confirmatory results.]
    H -->|TSH 15-39 mU/L| J[Borderline Elevated.<br>Requires Confirmatory Testing.]
    H -->|TSH < 11 mU/L| K[Normal / Negative Screen]
    
    I --> L[Mandatory Venous Confirmatory Testing:<br>TSH and Free T4 FT4]
    J --> L
    
    L --> M{Confirmatory Results}
    M -->|Low FT4, Elevated TSH| N[Primary Congenital Hypothyroidism]
    M -->|Low FT4, Low/Normal TSH| O[Central Congenital Hypothyroidism]
    M -->|Normal FT4, Low Total T4| P[TBG Deficiency]
    
    N --> Q[Initiate Oral Levothyroxine L-T4<br>Dose: 10-15 mcg/kg/day]
    
    K --> R{Identify High-Risk Populations}
    
    R -->|Preterm / Low Birth Weight<br>Monozygotic Twins<br>NICU Admissions<br>Trisomy 21 / Cardiac Defects| S[Mandatory Second Screen<br>at 2-4 weeks of life]
    R -->|None of the above| T[Routine Care]

Maturation of Fetal Hypothalamic-Pituitary-Thyroid (HPT) Axis

• Hypothalamus: Immunoreactive thyrotropin-releasing hormone (TRH) detectable in embryonic hypothalamus by 8-9 weeks postconception.
• TRH Kinetics: Fetal TRH concentrations relatively high due to combined hypothalamic/extrahypothalamic production and low TRH-degrading activity in fetal blood.
• Pituitary: TSH secretion evident by 10-12 weeks gestation.
• Vascular Integration: Pituitary-portal blood vessels form by 12-15 weeks; mature progressively through 30-35 weeks.
• TSH Kinetics: Fetal serum TSH increases from low basal levels at 18-20 weeks to peak values of 7-10 mU/L at term.
• Axis Maturation: HPT feedback control mechanisms mature throughout second half of gestation; adult-level set-points reached 1-3 months postnatally.

Placental Transfer Dynamics

Crucial maternal-fetal interface modulating fetal thyroid status. Hemochorial anatomy dictates differential permeability to thyroid-related molecules.

Substance	Placental Permeability	Clinical & Physiological Consequence
Iodine (I-)	Readily Permeable	Fetal thyroid entirely dependent on maternal iodine intake. Severe maternal deficiency restricts fetal T4 synthesis, causing endemic cretinism.
TRH	Readily Permeable	Maternal TRH can stimulate fetal TSH/T4. However, maternal circulating TRH levels are normally very low, exerting minimal physiologic effect on fetus.
TSH	Impermeable	Fetal thyroid stimulation strictly dependent on fetal pituitary TSH production.
T4 / T3	Partially Permeable	Maternal T4 crosses in physiologically relevant amounts. Provides ~33% of fetal T4 requirements at term. Critical for fetal brain development prior to fetal synthesis onset.
IgG Antibodies	Readily Permeable	Transplacental passage of TSH-receptor stimulating antibodies (TRSAbs) causes neonatal Graves disease. Blocking antibodies (TRBAbs) cause transient congenital hypothyroidism.
Thionamides	Readily Permeable	Maternal Methimazole or Propylthiouracil (PTU) therapy suppresses fetal thyroid. Risk of fetal goiter and transient neonatal hypothyroidism.

Fetal Thyroid Hormone Metabolism

• Metabolic Strategy: Fetal physiology heavily favors T4 inactivation. Prevents unnecessary tissue thermogenesis; potentiates rapid anabolic growth typical of fetal state.
• Sulfated Metabolites: Sulfated iodothyronines (T3S, T4S) constitute major circulating metabolites in fetus due to augmented iodothyronine sulfation and low clearance.
• Deiodinase Systems: Tissue-specific selenoenzymes dictate local and systemic thyroid status.

Deiodinase Type	Primary Fetal Locations	Enzymatic Action & Physiologic Role
Type I (DIO1)	Liver, Kidney, Thyroid	Converts T4 to active T3. Activity extremely low in fetus; surges postnatally.
Type II (DIO2)	Brain, Pituitary, Brown Adipose	Converts T4 to T3. Activity in fetal cerebral cortex increases 50% in 3rd trimester. Upregulated during hypothyroxinemia to ensure local T3 supply, protecting developing brain.
Type III (DIO3)	Placenta, Fetal Liver, Kidney	Rapidly degrades T4 to inactive reverse T3 (rT3) and T3 to T2. Predominant fetal enzyme, ensuring low circulating active T3 levels.

• Fetal Serum Hormone Profile:
  • T4 / FT4: Progressive increase from mid-gestation, reaching ~9.5 mcg/dL (T4) and 1.4 ng/dL (FT4) at term.
  • T3: Very low before 20 weeks; slow gradual rise to ~60 ng/dL at term.
  • Reverse T3 (rT3): Markedly elevated due to prominent DIO3 activity. Peaks at 300 ng/dL at 30 weeks; declines to 200 ng/dL at term.

Target Tissue Receptors & Transporters

• Membrane Transporters: Monocarboxylate transporter 8 (MCT8) strictly required for T3 entry into neurons across blood-brain barrier. MCT8 mutations cause profound psychomotor retardation (Allan-Herndon-Dudley syndrome).
• Nuclear Receptors (TR): Mediate gene transcription via TR-alpha 1 (predominant in bone, GI tract, heart, brain) and TR-beta 1/2 (liver, kidney, pituitary, cochlea).
• Ontogeny: TR binding detected in fetal brain by 10 weeks gestation. TR expression in cerebral cortex and cerebellum increases markedly during 2nd and 3rd trimesters.

Maternal Factors Influencing Fetal Thyroid Environment

• hCG Cross-Reactivity: Human chorionic gonadotropin (hCG) shares alpha-subunit homology with TSH. Peaks in 1st trimester. Excessively high levels (e.g., hyperemesis gravidarum, trophoblastic disease) activate maternal TSH receptors, elevating maternal T4/T3 and suppressing TSH (gestational thyrotoxicosis).
• Maternal T4 Contribution: Protective effect. Fetuses with true athyreosis rely on maternal T4. Term cord blood T4 in athyreotic infants is 30-50% of normal, sufficient to protect fetal brain from irreversible damage if promptly treated after birth.
• Maternal Autoimmunity:
  • Untreated maternal Graves disease leads to fetal exposure to TRSAbs → fetal tachycardia (>160 bpm), fetal goiter, advanced skeletal maturation, intrauterine growth restriction, and craniosynostosis.
  • Severe fetal thyrotoxicosis necessitates treating mother with antithyroid drugs to control fetal disease.

Perinatal Adaptation (The Postnatal Surge)

Immediate and profound transition required to shift from intrauterine anabolic state to extrauterine thermogenic independence.

• Cold-Stimulated TSH Surge: Abrupt exposure to cold extrauterine environment triggers massive hypothalamic TRH release and pituitary TSH surge.
• TSH Kinetics: Peaks rapidly at 30 minutes of life (70-100 mIU/L). Rapid initial decline within 24 hours, gradually normalizing to <5-10 mIU/L by 5-7 days.
• T4/T3 Surge: TSH surge stimulates massive glandular release. Serum T4 and T3 increase 2- to 6-fold, peaking at 2-3 days of life.
• Metabolic Shift: Hepatic DIO1 activity surges (stimulated by rising cortisol and T4). Reverses fetal pattern: T4-to-T3 conversion drastically increases. Placental separation simultaneously removes bulk DIO3 degradative capacity. Result: High sustained postnatal active T3.
• Thermogenesis Activation: High postnatal T3 acts synergistically with catecholamines on mature brown adipose tissue. Activates uncoupling protein (thermogenin) to dissipate mitochondrial proton gradient, driving crucial non-shivering thermogenesis to maintain neonatal body temperature.## Overview & Rationale

Neonatal Screening

• Goal: Early detection of Congenital Hypothyroidism (CH) to prevent irreversible intellectual disability.
• Incidence: 1 in 2,000 to 1 in 4,000 live births.
• Clinical Context: Universal screening mandatory. Infants characteristically asymptomatic at birth due to protective transplacental maternal thyroxine (T4) transfer.
• Window of Intervention: Irreversible neurodevelopmental damage occurs if untreated beyond early infancy.

Timing & Methodology

• Sample Collection: Dried blood spot (DBS) via heelprick on filter paper.
• Timing: 2 to 4 days (48-96 hours) of postnatal life.
• Physiologic TSH Surge: Cold-stimulated TRH-TSH surge peaks at 30 minutes of life (up to 70-100 mIU/L). Causes physiologic rise in T4 and T3.
• False Positives: Testing <24 hours yields high false positive rate due to this physiologic TSH surge.
• Alternative: Cord blood utilized if postnatal DBS unfeasible.

Screening Strategies

Strategy	Methodology	Advantages	Disadvantages
Primary TSH	Measures TSH only. Most common approach globally.	Highly sensitive for primary CH. Detects mild/compensated CH.	Misses central (secondary) CH. Misses delayed TSH elevations.
Primary T4 + Reflex TSH	Measures total T4. If <10th percentile, reflex TSH performed.	Detects primary CH, central CH, and Thyroxine-Binding Globulin (TBG) deficiency.	High false positive rate in prematurity (low TBG/T4). May miss mild primary CH with normal T4.

Thresholds & Interpretation

• Historical Cutoffs: TSH 20-50 mU/L.
• Modern Cutoffs: Lowered to 6-20 mU/L to detect milder variants.
• Age-Specific Action Thresholds:
  • Week 1: TSH >40 mU/L indicates immediate treatment.
  • Days 7-21: TSH >20 mU/L.
  • Beyond 21 Days: TSH >10 mU/L.

Example Algorithm (Québec Model)

• TSH < 11 mU/L: Normal.
• TSH $\ge$ 11 mU/L: Repeat in duplicate on initial blood spot.
• TSH $\ge$ 30 mU/L: Immediate referral & treatment.
• TSH 15-30 mU/L with T4 < 120 nmol/L: Immediate referral.

High-Risk Populations (Mandatory Second Screen)

Routine second screening at 2-4 weeks of life required for specific vulnerable groups:

• Preterm / Low Birth Weight (LBW): Prone to delayed TSH elevation. Immaturity of hypothalamic-pituitary-thyroid axis.
• Monozygotic Twins: True CH masked by fetal blood mixing from euthyroid twin (false negative on initial screen).
• NICU Admissions: Critical illness alters thyroid axis (euthyroid sick syndrome).
• Syndromic Associations: Trisomy 21, congenital cardiac defects.

Confirmatory Evaluation

• Venous Serum Testing: Mandatory diagnostic confirmation with venous TSH and Free T4 (FT4).
• Rule of Urgency: Treatment initiation MUST NOT be delayed awaiting confirmatory results if screening TSH >40 mU/L or strong clinical suspicion exists.
• Biochemical Profile:
  • Primary CH: Low FT4, Elevated TSH.
  • Central CH: Low FT4, Low/Normal TSH.
  • TBG Deficiency: Low Total T4, Normal FT4, Normal TSH.

Nuances & Pitfalls in Neonatal Screening

Iatrogenic & Environmental Interferences

• Iodine Excess (Wolff-Chaikoff Effect): Fetal/neonatal exposure to iodinated contrast media or topical iodine antiseptics (chlorhexidine preferred) causes transient hypothyroidism. Missed by initial screen if TSH rise occurs at 2-3 days.
• Dopamine Infusion: Potent suppressor of TSH secretion in premature infants. Masks elevated TSH.

Maternal Factors

• Antithyroid Drugs: Maternal methimazole/propylthiouracil crosses placenta. Causes transient neonatal hypothyroidism resolving in 2-5 days.
• TSH Receptor-Blocking Antibodies (TRBAb): Maternal autoimmune thyroid disease (Hashimoto/Graves) transfers TRBAbs. Causes transient CH persisting 3-6 months. Often yields absent uptake on scintigraphy mimicking agenesis.

Transient Hypothyroxinemia of Prematurity (THOP)

• Pathophysiology: Low Total T4, normal/low TSH in infants <28 weeks.
• Etiology: Loss of maternal T4 contribution, immature deiodinase activity, low intrathyroidal iodine stores.
• Management: Observation. T4 spontaneously corrects by 6 weeks. Prophylactic levothyroxine yields no neurodevelopmental benefit.